Soleno Therapeutics Company Leadership
| SLNO Stock | USD 46.88 0.89 1.94% |
Soleno Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Soleno Therapeutics suggests that virtually all insiders are panicking. Soleno Therapeutics employs about 33 people. The company is managed by 13 executives with a total tenure of roughly 12 years, averaging almost 0.0 years of service per executive, having 2.54 employees per reported executive.
| Anthony Wondka President Vice President - Research and Development |
Soleno Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2025-01-03 | Kristen Yen | Disposed 2340 @ 46.18 | View | ||
| 2025-01-02 | James H Mackaness | Disposed 4083 @ 45.41 | View | ||
| 2024-10-01 | Kristen Yen | Disposed 3108 @ 49.43 | View | ||
| 2024-08-29 | Vivo Opportunity, Llc | Disposed 100000 @ 47.22 | View | ||
| 2024-08-28 | Kristen Yen | Disposed 5270 @ 47.58 | View | ||
| 2024-08-27 | Vivo Opportunity, Llc | Disposed 500000 @ 48.73 | View | ||
| 2024-08-05 | James H Mackaness | Disposed 6849 @ 45.77 | View | ||
| 2024-07-01 | Kristen Yen | Disposed 2170 @ 41.54 | View | ||
| 2024-04-29 | Vivo Opportunity, Llc | Disposed 750000 @ 47.8 | View | ||
| 2024-04-01 | James H Mackaness | Disposed 5175 @ 41.34 | View |
Monitoring Soleno Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Soleno |
Soleno Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Soleno Therapeutics' future performance. Based on our forecasts, it is anticipated that Soleno will maintain a workforce of about 30 employees by February 2025.Soleno Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4805) % which means that it has lost $0.4805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9111) %, meaning that it created substantial loss on money invested by shareholders. Soleno Therapeutics' management efficiency ratios could be used to measure how well Soleno Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of January 2025, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to drop to -0.3. At this time, Soleno Therapeutics' Total Assets are very stable compared to the past year. As of the 19th of January 2025, Other Current Assets is likely to grow to about 2 M, while Non Current Assets Total are likely to drop about 9.9 M.As of the 19th of January 2025, Common Stock Shares Outstanding is likely to grow to about 19.9 M, while Net Loss is likely to drop (22.7 M).
Soleno Therapeutics Workforce Comparison
Soleno Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,010. Soleno Therapeutics holds roughly 33.0 in number of employees claiming about 3% of equities under Health Care industry.
Soleno Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Soleno Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Soleno Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Soleno Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 0.1702 | 8 | 47 | 1,353,000 | 1,370,041 |
| 2024-06-01 | 0.4615 | 6 | 13 | 94,500 | 1,439,833 |
| 2024-03-01 | 2.0 | 8 | 4 | 423,000 | 7,279 |
| 2023-12-01 | 0.2381 | 10 | 42 | 5,265,868 | 5,560,836 |
| 2023-09-01 | 10.0 | 20 | 2 | 5,426,938 | 4,295,149 |
| 2022-09-01 | 0.3889 | 7 | 18 | 2,500,000 | 180,523 |
| 2022-03-01 | 7.3333 | 22 | 3 | 48,929,507 | 53,185 |
| 2021-12-01 | 3.0 | 3 | 1 | 64,196 | 6,373 |
| 2021-09-01 | 0.8 | 4 | 5 | 63,707 | 177,398 |
| 2021-06-01 | 1.5714 | 11 | 7 | 294,359 | 877,987 |
| 2021-03-01 | 0.5455 | 12 | 22 | 2,966,810 | 1,045,850 |
| 2020-12-01 | 0.6667 | 4 | 6 | 324,568 | 265,104 |
| 2020-06-01 | 9.5 | 19 | 2 | 15,055,203 | 200,243 |
| 2019-12-01 | 0.2778 | 5 | 18 | 7,173,750 | 626,149 |
| 2019-06-01 | 10.0 | 30 | 3 | 501,693 | 80,868 |
| 2019-03-01 | 8.5 | 17 | 2 | 968,387 | 94,000 |
| 2016-06-01 | 7.6667 | 23 | 3 | 1,001,100 | 133,419 |
| 2016-03-01 | 2.0 | 12 | 6 | 1,350,688 | 160,464 |
| 2015-12-01 | 1.5 | 6 | 4 | 3,341,618 | 787,716 |
| 2015-09-01 | 1.8 | 18 | 10 | 5,021,311 | 1,155,188 |
| 2015-06-01 | 2.75 | 11 | 4 | 326,999 | 79,999 |
| 2015-03-01 | 11.0 | 11 | 1 | 307,666 | 13,097 |
| 2014-12-01 | 1.3014 | 95 | 73 | 13,419,403 | 48,187,575 |
Soleno Therapeutics Notable Stakeholders
A Soleno Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Soleno Therapeutics often face trade-offs trying to please all of them. Soleno Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Soleno Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Anthony Wondka | Vice President - Research and Development | Profile | |
| Kristen MS | Senior Operations | Profile | |
| Dr MBA | Senior Development | Profile | |
| Patricia MPH | Senior Affairs | Profile | |
| PharmD MBA | Senior Affairs | Profile | |
| Meredith MBA | Chief Officer | Profile | |
| Anish MD | CEO and President | Profile | |
| Jesse Schumaker | General Counsel | Profile | |
| James MacKaness | Chief Officer | Profile | |
| Lauren Budesheim | Vice People | Profile | |
| Michael MD | Senior Development | Profile | |
| Patricia Hirano | Vice Affairs | Profile |
About Soleno Therapeutics Management Performance
The success or failure of an entity such as Soleno Therapeutics often depends on how effective the management is. Soleno Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Soleno management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Soleno management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.28) | (0.30) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.28) | (0.30) |
Soleno Therapeutics Workforce Analysis
Traditionally, organizations such as Soleno Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Soleno Therapeutics within its industry.Soleno Therapeutics Manpower Efficiency
Return on Soleno Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 3M | |
| Working Capital Per Employee | 4.8M | |
| Working Capital Per Executive | 12.3M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.